Virginia Powers, PhD

Articles

Second-Line Cetuximab Shows PFS Benefit in Wild-Type mCRC

July 4th 2015

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR

July 4th 2015

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

Regorafenib Benefits Consistent in "Real World" mCRC Population

July 3rd 2015

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

Improved OS, PFS Demonstrated by TAS-102, Regardless of KRAS Status

July 3rd 2015

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

New Agents Show Promise in Gastric Cancer

July 3rd 2015

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.

Hepatitis C "Revolution" May Transform Liver Cancer Outcomes

July 2nd 2015

Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma and have shown the ability to reverse liver fibrosis, including cirrhosis in patients with end-stage HCC.

IMM-101 Active, Maintains QoL in Patients with Metastatic Pancreatic Cancer

July 2nd 2015

Investigators reported a clinically meaningful extension of overall survival with IMM-101 plus gemcitabine in patients with metastatic pancreatic cancer.

Low BMI Prognostic for Worse Survival in Colorectal Cancer

July 1st 2015

Results from a pooled dataset of more than 6000 patients with metastatic colorectal cancer found an association between low body mass index and a worse median overall survival with first-line bevacizumab and chemotherapy, suggesting that low BMI could be a prognostic factor for worse outcomes.

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

June 20th 2015

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

Venetoclax Combination Shows Antitumor Activity in Advanced Myeloma

June 20th 2015

A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.

Lenalidomide Highly Effective in Early Phase CNS Lymphoma Study

June 20th 2015

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

Ibrutinib, Ublituximab, TGR-1202 Triplet Active in Relapsed B-Cell Malignancies

June 19th 2015

A chemotherapy-free combination of the anti-CD20 antibody ublituximab, ibrutinib, and the PI3K delta inhibitor TGR-1202 demonstrated robust clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma.

PI3KÎ´ and JAK1 Inhibitors Show Promise in Advanced Hodgkin Lymphoma

June 19th 2015

The PI3KÎ´ inhibitor INCB040093 alone or in combination with the JAK1 inhibitor INCB039110 showed early promise in relapsed/refractory classical Hodgkin lymphoma.

Nivolumab Elicits Durable Responses in Lymphoma

June 19th 2015

Nivolumab continued to show high activity and a good safety profile after more than a year of follow-up in heavily pretreated patients with relapsed or refractory lymphoid malignancies or those with classical Hodgkin lymphoma.

Rituximab, Thiotepa, and Chemo Combo Improves Outcomes in Primary CNS Lymphoma

June 18th 2015

The MATRIX regimen, comprised of a methotrexate/cytarabine backbone plus thiotepa and rituximab, improved outcomes in patients with primary CNS lymphoma.

SYK Inhibitor TAK-659 Shows Promising Results in Lymphoid Malignancies

June 18th 2015

TAK-659, an inhibitor of spleen tyrosine kinase, showed early signs of antitumor activity in patients with lymphoma, with two expansion arms planned for patients with diffuse large B-cell lymphoma and chronic lymphocytic leukemia.

Interim FDG-PET Scans Enable Response-Adapted Therapy in Hodgkin Lymphoma

June 18th 2015

Interim PET-CT scanning was successfully used to adapt treatment regimens in patients with advanced classical Hodgkin lymphoma.

Cetuximab, Bevacizumab Equivalent as First-Line Therapy in KRAS Wild-Type mCRC

June 28th 2014

A head-to-head comparison of cetuximab and bevacizumab in a phase III trial that was nearly 10 years in the making showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated metastatic colorectal cancers.

Palliative Resection Associated With Improved Survival in mCRC

June 28th 2014

Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.

Active Maintenance Improves PFS in mCRC

June 28th 2014

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer.